Review Article Cytomegalovirus management after allogeneic hematopoietic stem cell transplantation: A mini-review

doi:10.1016/j.jmii.2021.01.001

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 其他文獻 > Item 310902500/24232

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24232

题名:	Review Article Cytomegalovirus management after allogeneic hematopoietic stem cell transplantation: A mini-review
作者:	Teng, CLJ;Wang, PN;Chen, YC;Ko, BS
关键词:	Allogeneic hematopoietic stem cell transplantation;Cytomegalovirus;Prophylaxis;Preemptive;Ganciclovir
日期:	2021
上传时间:	2022-08-05T10:45:12Z (UTC)
出版者:	ELSEVIER TAIWAN
ISSN:	1684-1182
摘要:	Because of the high incidence of cytomegalovirus (CMV) seropositivity in the population, CMV infection is a common and severe complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in Taiwan. Here we propose a CMV management strategy for patients undergoing allo-HSCT from the Taiwanese perspective, which focuses on the epidemiology, diagnosis, monitoring, prophylaxis, and treatment of CMV infection after allo-HSCT. In terms of CMV monitoring, weekly CMV monitoring with the COBAS (R) AmpliPrep system is the standard approach because the pp65 CMV antigenemia assay has a lower sensitivity than CMV monitoring with the COBAS (R) AmpliPrep system. However, pp65 CMV antigenemia assay has a better correlation with clinical symptoms in immunocompromised patients. A 14-week prophylactic course of letermovir is recommended for allo-HSCT recipients in Taiwan, especially for recipients of hematopoietic stem cells from mismatched unrelated and haploidentical donors. Preemptive ganciclovir therapy should be initiated when the CMV viral load exceeds 1000 copies/mL, and should not be discontinued until CMV DNA is no longer detectedin the blood. For allo-HSCT recipients who have CMV-related diseases, ganciclovir with or without CMV-specific intravenous immunoglobulin is the standard of care. The limited availability of foscarnet, an alternative for patients who are not responsive to or cannot tolerate ganciclovir, is a crucial issue in Taiwan. For pediatric allo-HSCT recipients, more data are needed to propose a CMV management recommendation. Copyright (c) 2021, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/).
URI:	http://dx.doi.org/10.1016/j.jmii.2021.01.001 https://www.webofscience.com/wos/woscc/full-record/WOS:000664639400001 https://ir.csmu.edu.tw:8080/handle/310902500/24232
關聯:	JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION ,2021 ,v54 ,issue3 ,p348-348
显示于类别:	[中山醫學大學研究成果] 其他文獻

文件中的档案:

档案	描述	大小	格式	浏览次数
index.html		0Kb	HTML	307	检视/开启

在CSMUIR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....